Opus Genetics (IRD) COO sells shares to cover tax withholding

Rhea-AI Filing Summary

Opus Genetics, Inc. Chief Operating Officer Joseph K. Schachle reported an automatic share sale tied to tax withholding. On this transaction, 4,697 shares of common stock were sold at $5.2202 per share to satisfy tax obligations arising from a restricted stock unit vesting and settlement event. The filing notes this was not a discretionary trade by the executive. After the sale, Schachle directly holds 296,084 shares of Opus Genetics common stock.

Insider Trade Summary

Net Seller: 4,697 shares ($24,519)

Net Sell 1 txn

Insider SCHACHLE JOSEPH K

Role Chief Operating Officer

Sold 4,697 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,697	$5.2202	$25K

Holdings After Transaction: Common Stock — 296,084 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 4,697 shares Sale price per share: $5.2202 per share Shares held after transaction: 296,084 shares

3 metrics

Shares sold 4,697 shares Automatic sale on April 23, 2026 to satisfy tax withholding

Sale price per share $5.2202 per share Price for common stock sold in tax-related transaction

Shares held after transaction 296,084 shares Direct common stock holdings of COO after tax withholding sale

Key Terms

restricted stock units, tax withholding obligations, vesting and settlement event, non-discretionary trade

4 terms

restricted stock units financial

"a vesting and settlement event from a restricted stock units award"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold automatically ... to satisfy tax withholding obligations that arose"

vesting and settlement event financial

"that arose in connection with a vesting and settlement event from a restricted stock units award"

non-discretionary trade financial

"This transaction does not represent a discretionary trade by the Reporting Person"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHACHLE JOSEPH K

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S(1)		4,697	D	$5.2202	296,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

	/s/ Amy Rabourn, by Power of Attorney	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Opus Genetics (IRD) report in this Form 4?

Opus Genetics reported that COO Joseph K. Schachle had 4,697 common shares sold at $5.2202 each. The sale covered tax withholding obligations from a restricted stock unit vesting and was executed automatically, not as a discretionary market trade.

Was the Opus Genetics (IRD) COO’s share sale a discretionary trade?

No, the filing states the sale was executed automatically to satisfy tax withholding obligations from a restricted stock unit vesting. It explicitly notes the transaction does not represent a discretionary trade by the reporting person in the company’s common stock.

How many Opus Genetics (IRD) shares did the COO sell and at what price?

The COO had 4,697 shares of Opus Genetics common stock sold at $5.2202 per share. These shares were liquidated solely to cover tax withholding obligations connected to a restricted stock unit vesting and settlement event, rather than a voluntary portfolio decision.

How many Opus Genetics (IRD) shares does the COO hold after this transaction?

Following the tax-related sale, COO Joseph K. Schachle directly holds 296,084 shares of Opus Genetics common stock. This post-transaction holding shows he maintains a substantial equity position in the company despite the automatic sale to cover tax obligations.

What triggered the tax withholding sale for Opus Genetics (IRD) COO?

The sale was triggered by a vesting and settlement event from a restricted stock unit award. When those units vested, tax withholding obligations arose, and the company automatically sold 4,697 shares on the COO’s behalf to satisfy those obligations, according to the filing footnote.

Does the Opus Genetics (IRD) Form 4 indicate any remaining derivatives for the COO?

The Form 4 summary shows no derivative transactions in this filing and an empty derivative position list. The reported activity involves only a common stock sale related to tax withholding, with no additional options, warrants, or similar derivative positions disclosed here.